Ricevi le ultime notizie sulle azioni Eledon Pharmaceuticals con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ELDN

Ultime notizie per

ELEDON PHARMACEUTICALS INC

Eledon Pharma

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals Inc

Earnings

Press Releases

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

Updated Data from Eledon Pharmaceuticals' Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

News

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

ELDN

SEOVF

TSX:SVA

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Alpha Cognition

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Avalo Therapeutics

Biomea Fusion

C4 Therapeutics

Compugen

Coherus Oncology

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Citius Oncology

Eledon Pharmaceuticals

Elicio Therapeutics

Fate Therapeutics

Forte Biosciences

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Genfit

Genelux

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Seres Therapeutics

Nkarta

Nuvectis Pharma

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Pyxis Oncology

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

HC Wainwright & Co.

Craig-Hallum

Noble Capital Markets

Cantor Fitzgerald

Screenshot 2025-03-12 at 4.47.01 PM

Biotech

General

AMGN

BIIB

TNXP

Tonix&#39;s TNX-1500 Shows Promise In Preventing Organ Transplant Rejections Of Either Human Or Pig Organs; Autoimmune Diseases Also A Target

Comments

Eledon Pharmaceuticals Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO